Zhitong Finance App News, Jin Dawei (002626.SZ) issued an announcement. Recently, Inner Mongolia Jindaway Pharmaceutical Co., Ltd. (hereinafter referred to as “Jindaway Pharmaceutical”), a wholly-owned subsidiary of the company, received a letter of no objection from GRAS Notice No. GRN 001305 issued by the US Food and Drug Administration (FDA). Jindaway Pharmaceuticals' Brazilian sweet protein (Brazzein preparation) product has completed the FDA GRAS notification evaluation, and the FDA has issued no objections to the GRAS (GRAS) conclusion under the declared use of this product.
Brazzein preparation (Brazzein preparation) is a high-protein sweetener. The sweetness is about 500-2000 times that of sucrose. It can be used as a general sweetener in the food field, and has good compounding compatibility. Brazilian sweet protein does not participate in the body's glucose metabolism pathway, does not raise blood sugar, is broken down into amino acids after entering the human body, provides almost no calories, adapts to the needs of sugar control people and fat loss people, and has broad market application prospects.
Jindawei Pharmaceutical's Brazilian sweet protein product obtained a letter of no objection from the US FDAGRAS, indicating that the safety findings of the product have passed the FDA's official review and have not been objected to. The product has an important compliance foundation for entering the US food market, which helps the company's related products expand overseas markets, enrich the company's product matrix and revenue sources for food ingredients, and enhance the company's overall competitiveness in the field of synthetic biology. It is expected to have a positive impact on the company's future development.